Clinical Trials in North Carolina

Showing 6381-6400 of 20,428 trials

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

NCT03485729

This was a Phase 2, Simon two-stage, non-randomized, open-label, 2-arm trial of dordaviprone (ONC201) in women with metastatic or recurrent Type II endometrial cancer who failed at least 1 prior chemotherapy regimen. Patients with histologically confirmed Type II endometrial cancer, including but not limited to serous, clear cell, carcinosarcoma, adenosquamous, and mixed histologies were eligible. The primary objective of this study was to determine the efficacy of dordaviprone (ONC201) in metastatic type II endometrial cancer. Note: This study was completed by predecessor company, Oncoceutics, Inc.

Endometrial Cancer Recurrent

Jazz Pharmaceuticals27 participantsStarted Mar 2018

New Brunswick, New Jersey, United States • Chapel Hill, North Carolina, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPhase 346 miles

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

NCT03623321

The purpose of this study is to evaluate the long-term safety and tolerability of pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease exposed to open-label pimavanserin for up to 52 weeks.

Neuropsychiatric Symptoms Related to Neurodegenerative Disease

ACADIA Pharmaceuticals Inc.595 participantsStarted Jul 2018

Gilbert, Arizona, United States • Costa Mesa, California, United States • Santa Ana, California, United States +85 more locations

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Find Trials by Condition in North Carolina

Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

Chimney EndoVascular Aneurysm Sealing Of New Expanded Indication

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Opioid-Free Anesthetic for Tonsillectomy

Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

CYPRESS Efficacy and Safety Study Extension

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Oral ONC201 in Adult Recurrent Glioblastoma

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Global Fenestrated Anaconda Clinical STudy